FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
_	OMB Number:	3235-0287								
	Estimated average burden									

hours per response:

0.5

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

					1 01 3	Jecui	011 30(11	) Of the f	IIVESIIII	THE CO	прапу Аст	01 13	740						
1. Name and Address of Reporting Person*  COZADD BRUCE C					2. Issuer Name <b>and</b> Ticker or Trading Symbol  Jazz Pharmaceuticals plc [ JAZZ ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
COZADD BRUCE C														X Dire		ctor 10%		Owner	
(Last)	/Ei	ret) (	Middle)		3 D	2. Data of Fauliant Transpostion (Month/Dou/Mont)									X	Office	er (give title w)	Other below	(specify
						3. Date of Earliest Transaction (Month/Day/Year) 03/09/2012											,	n and CEO	- /
C/O JAZZ PHARMACEUTICALS PLC					05/05/2012														
45 FITZWILLIAM SQUARE																			
,				- 4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)															X	Form	n filed by One	e Reporting Per	son
DUBLIN	2 L2	-															,	re than One Re	
					1											Pers		c than one re-	porting
(City)	(St	ate) (	Zip)																
		Tabl	e I - Noi	n-Deriv	ative	Se	curiti	es Acc	quired	, Dis	posed o	f, o	r Ben	efici	ally (	Owne	ed		
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		Code	Transaction Dispose Code (Instr. 5)		ties Acquired (A) d Of (D) (Instr. 3, 4			4 and Secu Bene Own		cially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount		(A) or (D)	Price			action(s) 3 and 4)		(Instr. 4)
Ordinary Shares 03.				03/09	03/09/2012						50,000	0	D	\$49.56		49	7,066 <sup>(1)</sup>	D	
		Та									osed of, onvertib				y Ov	vned			•
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		te	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		str. 3	8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	or Nui of	ount nber ares					

## **Explanation of Responses:**

1. On March 9, 2012, the Reporting Person completed the sale of 50,000 ordinary shares to Barclays Capital Inc. and Citigroup Global Markets Inc., as underwriters in connection with a public offering of a total of 7,883,366 ordinary shares by certain shareholders of the Issuer, including the Reporting Person.

## Remarks:

<u>/s/ Bruce Cozadd</u> 03/12/2012

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.